Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 19   

Articles published

KYTH 35.25 -1.12 (-3.08%)
price chart
Kythera Biopharmaceuticals CEO Keith R. Leonard Sells 1913 Shares (KYTH)
On average, analysts predict that Kythera Biopharmaceuticals will post $-3.34 earnings per share for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and ...
Kythera Biopharmaceuticals Inc. (KYTH) Jumps 5.77% on October 23
Kythera Biopharmaceuticals Inc. ($KYTH) was among the biggest gainers on the Russell 2000 for October 23 as the stock popped 5.77% to $36.11, representing a gain of $1.97 per share.
Related articles »  
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program
KYTHERA Biopharmaceuticals, Inc. KYTH, -4.57% today announced that on October 17, 2014, the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase an aggregate of 28,500 shares of the ...
Related articles »  
Insider Selling: Kythera Biopharmaceuticals CEO Unloads 1913 Shares of Stock ...
On average, analysts predict that Kythera Biopharmaceuticals will post $-3.34 earnings per share for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and ...
Related articles »  
Kythera Biopharmaceuticals Inc. (KYTH) Jumps 5.49% on October 8
Kythera Biopharmaceuticals Inc. (KYTH) was among the biggest gainers on the Russell 2000 for October 8 as the stock popped 5.49% to $32.86, representing a gain of $1.71 per share.
Related articles »  
Insider Selling: Kythera Biopharmaceuticals CEO Unloads 3826 Shares of Stock ...
Analysts expect that Kythera Biopharmaceuticals will post $-3.34 earnings per share for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization ...
Insider Selling: Nathaniel E. David Unloads 1350 Shares of Kythera ...  WKRB News
Related articles »  
Best Stocks:SouFun Holdings (NYSE:SFUN), FireEye (NASDAQ:FEYE), Kythera ...
On last trading day Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) moved up 0.11% to close at $36.80. Its volatility for the week is 3.85% while volatility for the month is 4.79%.
Related articles »  
Drugs Industry Update: Epizyme, Genomic Health, Kythera Biopharma ...
Epizyme, Inc. (NASDAQ:EPZM) : Announced the appointments of Peter Ho, as Chief Development Officer and Michael Shih, as Vice President, Business Development.
Related articles »  
Kythera Biopharmaceuticals Director Sells $44010 in Stock (KYTH)
Analysts expect that Kythera Biopharmaceuticals will post $-3.34 EPS for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription ...
Related articles »  
Zeltiq Aesthetics (ZLTQ) Earnings Report: Will It Slim or Fatten Investor ...
The Q3 2014 earnings report for small cap aesthetic medical device Zeltiq Aesthetics Inc (ZLTQ), a potential peer or benchmark for stocks like Kythera Biopharmaceuticals Inc (KYTH) and Cynosure, Inc (CYNO) that also focus on aesthetic applications like ...